|
Jul 23
|
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
|
|
Jul 15
|
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
|
|
Jun 30
|
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
|
|
Jun 27
|
Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
|
|
Jun 27
|
Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
|
|
Jun 25
|
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
|
|
Jun 24
|
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
|
|
Jun 23
|
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
|
|
Jun 12
|
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
|
|
Apr 17
|
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
|
|
Apr 16
|
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
|
|
Mar 14
|
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
|
|
Feb 28
|
Psychedelic: GH Research, Compass Pathways report earnings results
|
|
Jan 2
|
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
|
|
Oct 10
|
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
|
|
Aug 29
|
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
|
|
Jul 31
|
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
|
|
Jun 11
|
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
|
|
Apr 30
|
Clearmind Applies to Cease Being a Reporting Issuer in Canada
|
|
Feb 11
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|